C16orf58 Inhibitors

LY294002 and Wortmannin are both phosphoinositide 3-kinases (PI3K) inhibitors that can inhibit downstream signaling pathways, which may be regulated by or involve C16orf58. PD98059 and U0126 are MEK inhibitors that can suppress the MAPK/ERK pathway, potentially affecting the processes where C16orf58 is implicated. SB203580, a p38 MAPK inhibitor, and SP600125, a JNK inhibitor, can respectively interfere with the p38 and JNK MAPK signaling pathways, which C16orf58 might influence.

Rapamycin, an mTOR inhibitor, is well known for its role in inhibiting cell growth and proliferation pathways that C16orf58 may affect. PP2, as a Src family kinase inhibitor, and BAY 11-7082, an NF-κB inhibitor, can modify various signaling mechanisms and transcriptional regulation processes that C16orf58 could be associated with. BML-275, an AMPK inhibitor, can impact energy metabolism signaling pathways, hence potentially influencing C16orf58's role within these pathways. Y-27632, a ROCK inhibitor, can affect cytoskeletal organization and related signaling pathways, which could include processes regulated by C16orf58. MG132, a proteasome inhibitor, can influence the degradation pathways of proteins, thereby potentially altering the stability and turnover of C16orf58.